e-Edition
Obituaries
Special Sections
Special Occasions
Contact

Subscribe
Paywall Login
Login to Comment
Register

December 11th, 2017

jobs

homes

Home
News
Sports
Business
Entertainment
Classifieds
Commentary

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Genmab A/S - American Depositary Shares (NQ:GMAB)

26.97 +0.52 (+1.97%)

Streaming Delayed Price Updated: 3:12 PM EDT, May 4, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Genmab A/S - American Depositary Shares

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

AbbVie - Genmab Present Epcoritamab Data From Lymphoma Trial ↗

June 13, 2022

Via Benzinga

Genmab Announces Late-Breaking Phase 2 Trial Results of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Relapsed/Refractory Large B-cell Lymphoma (LBCL) Patients Presented at European Hematology Association (EHA) Presidential Symposium

June 11, 2022

From Genmab

Via Business Wire

Seagen and Genmab Present Data from Tisotumab Vedotin (TIVDAK®) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting

June 06, 2022

From Seagen Inc.

Via Business Wire

Analyst Ratings for Genmab ↗

May 12, 2022

Within the last quarter, Genmab (NASDAQ:GMAB) has observed the following analyst ratings:

Via Benzinga

Genmab and Seagen Present Data from Tisotumab Vedotin (TIVDAK®) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting

June 06, 2022

From Genmab A/S

Via Business Wire

Genmab Announces Multiple Abstracts to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

May 26, 2022

From Genmab

Via Business Wire

Johnson & Johnson Stock: A Rare Bright Spot in the Market ↗

May 14, 2022

JNJ stock is up on the year thanks in part to its steadily rising dividend, which investors covet during the current market volatility.

Via InvestorPlace

Genmab Announces Multiple Abstracts to Be Presented at the European Hematology Association (EHA) Annual Congress

May 12, 2022

From Genmab

Via Business Wire

The Daily Biotech Pulse: Veru Shares Up On COVID Candidate Update, FDA Approves Lilly's COVID Treatment, Latest On Sanofi-AstraZeneca RSV Vaccine ↗

May 11, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 2, 2022 ↗

May 02, 2022

Upgrades

Via Benzinga

The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Booster Data In Kids, Regeneron's COVID-19 Therapy Decision Pushed, Protagonist's Rusfertide Breakthrough Tag Update And More ↗

April 14, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

AbbVie - Genmab Post Epcoritamab Data From Early-Stage Blood Cancer Study ↗

April 14, 2022

Genmab A/S (NASDAQ: GMAB) and AbbVie Inc (NYSE: ABBV)

Via Benzinga

Genmab and AbbVie Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) From Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL)

April 13, 2022

From Genmab A/S

Via Business Wire

BioNTech And Matinas BioPharma Announce Exclusive Research Collaboration To Evaluate Novel Delivery Technology For mRNA-based Vaccines ↗

April 11, 2022

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

Via Benzinga

Janssen Partner Genmab Loses Arbitration Over Darzalex Royalties ↗

April 08, 2022

Via Benzinga

Best Biotech Stocks To Buy In 2022 ↗

March 15, 2022

Biotechnology is the study of living creatures, biological systems, or derivatives to develop or improve healthcare products and therapies. This technology is connected with medical and...

Via Talk Markets

Seagen and Genmab Present First Data on Tisotumab Vedotin (TIVDAK®) in Patients with Head and Neck Squamous Cell Carcinoma

February 24, 2022

From Seagen Inc.

Via Business Wire

Genmab and Seagen Present First Data on Tisotumab Vedotin (TIVDAK®) in Patients with Head and Neck Squamous Cell Carcinoma

February 24, 2022

From Genmab A/S

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2022 ↗

January 31, 2022

Upgrades UBS upgraded the previous rating for Align Technology Inc (NASDAQ:ALGN) from Neutral to Buy. For the third quarter, Align Tech had an EPS of $2.87, compared to year-ago...

Via Benzinga

A Bearish Sign Looms Over Genmab's Chart ↗

December 31, 2021

If history is any guide, there may be trouble ahead for shares of Genmab (NASDAQ:GMAB). A so-called "death cross" has formed on its chart and, not surprisingly, this...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For January 3, 2022 ↗

January 03, 2022

Upgrades For nVent Electric PLC (NYSE:NVT), Vertica...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For December 1, 2021 ↗

December 01, 2021

Upgrades Goldman Sachs upgraded the previous rating for Grupo Aeroportuario del Sureste SAB de CV

Via Benzinga

Genmab A/S (GMAB) Q3 2021 Earnings Call Transcript ↗

November 20, 2021

GMAB earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance ↗

November 10, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus MorphoSys COO To Leave To Pursue Other Opportunities MorphoSys AG (NASDAQ:...

Via Benzinga

The Daily Biotech Pulse: NRx's Zyesami Face Regulatory Rejection, Puma Slumps On Q3 Miss, Pfizer Has Good Tidings On Oral Antiviral COVID-19 Pill ↗

November 05, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus NRx's COVID-19 Drug Fails to Get Authorization From FDA Due To...

Via Benzinga

The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More ↗

November 08, 2021

Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out...

Via Benzinga

Genmab Announces Multiple Abstracts to be Presented at the 63rd Annual Meeting and Exposition of the American Society of Hematology (ASH)

November 04, 2021

From Genmab A/S

Via Business Wire

Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates ↗

October 01, 2021

Following a mixed month for regulatory approvals, biotech investors now turn toward a month of plenty as far as Food and Drug Administration decisions are concerned. Four new...

Via Benzinga

Genmab Announces Abstracts Evaluating Investigational Solid Tumor Therapies to be Presented at the Society for Immunotherapy of Cancer’s 36th Annual Meeting (SITC 2021)

October 01, 2021

From Genmab

Via Business Wire

Why Genmab's Stock Is Trading Higher Today ↗

September 21, 2021

Genmab A/S (NASDAQ:GMAB) shares are trading higher after the company, along with Seagen Inc. (NASDAQ: SGEN), announced the FDA has granted accelerated approval to...

Via Benzinga

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

More ways to get to us

Facebook

Twitter

YouTube

ePaper Login
Subscribe
Subscription Services
Archive

About Us

The Lethbridge Herald
Other Publications
Food For Thought

Contact
Careers

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

Advertising
Terms and Conditions & Privacy Policy